First sound pharmaceutical industry to Hong Kong listing! Last year's total revenue of 5,037 million yuan Nearly 50 innovative drugs in research.

On June 10, FirstSound PharmaceuticalS Group Co., Ltd. (hereinafter referred to as: First sound pharmaceutical industry) submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CICC acting as their co-sponsors.
Pioneer Pharmaceuticals was founded in 1995, is a drug research and development, production and sales of a new pharmaceutical group.
April 20, 2007, First Sound Pharmaceuticals successfully landed in the U.S. stock market, raising $226 million and a market capitalization of more than $1 billion, becoming the first Chinese chemical biopharmaceutical company to list on the New York Stock Exchange.
2014, First Voice Pharmaceuticals completed privatization and delisted its U.S. stock market.
30 products have been on the market for 25 years, the first sound pharmaceutical industry focused on the tumor, central nervous system and autoimmune three major disease areas of drug research and development, production and commercialization, and formed a rich product pipeline.
, in the field of cancer disease, the first sound pharmaceutical industry has Endu (recombinant human vascular endothelial inhibitor injection), Jielushu (injection of neda platinum), Terielli (Pemequse dsodium) and chinese fluoroan (5-fluoruineth implant implants) and other 5 listed products; In the field of neurological diseases, First Sound Pharmaceuticals has three listed products, including The Deposit (Idalafon injection), and in the field of autoimmune diseases, First Sound Pharmaceuticals has four listed products with Aedesai (Iramod tablets) and Ether inthem (sodium doflfenate relief capsules and gels) as the core.
In addition, in the field of cardiovascular disease, first-sound pharmaceutical industry has schiffan (rusevastatatin calcium) and other three products on the market, as well as in the field of anti-infectious diseases, the first sound pharmaceutical industry has an ansin (injection bi-Apenan), relin (Amoxilin) and Reli (Kabidol dispersal tablets) 15 products listed.
, according to the prospectus, the operating income of First Sound Pharmaceuticals increased from RMB3,868 million in 2017 to RMB5,037 million in 2019, with a CAGR of 14.1%, and net profit increased from RMB350 million in 2017 to RMB1,004 million in 2019, with an annual COMPOUND growth rate of 69.2%. Among the
, sales of tumor disease products in the first sound pharmaceutical industry reached 1,569 million yuan in 2019, accounting for 32.7% of the total sales of drugs during the same period;
nearly 50 innovative drugs in the research prospectus disclosed that up to now, the first sound pharmaceutical industry has nearly 50 in different stages of development in the research and innovation drug products, including small molecule drugs, macromolecule drugs and CAR-T cell therapy, of which more than 10 in the research innovative drug products in the clinical stage, has submitted a new drug declaration or has been approved.
first sound pharmaceutical innovation in the research pipeline, which is noteworthy, from 2020 to 2021, the first sound pharmaceutical industry or will be listed in the three heavy innovative drug products: 1 innovative drug Idaraalcohol injection with a concentrated solution (Idalafu compound preparation), PD-LI inhibitor KN035 (Envafob) and imported innovative drug Oriacia (Abassia injection).
Idala fong rightalcohol injection thick solution, is a sound pharmaceutical industry after 13 years of independent research and development with independent intellectual property rights of a class of innovative drugs, is expected to become the world's only approved for sale of new stroke drugs in the past 5 years.
compared with other stroke treatment drugs, Idala is a concentrated solution with rightalcohol injection.
KN035 (Envafolimab) is a subcutaneous injection of PD-L1 monotorine developed by Corning Jerry.
March 2020, First Sound Pharmaceuticals signed a cooperation agreement with Corning Jerry and Thoughti Pharmaceuticals, which grants First Sound Pharmaceuticals exclusive rights to market and promote KN035 in All Tumor Indications in China.
is currently conducting Phase II clinical trials of DMMR/MSI-H colorectal cancer and other advanced solid tumors of KN035 and Phase III clinical trials of advanced BTC in China, as well as Phase I clinical trials in the United States and Japan.
expects to submit applications for new drugs to china in the second half of 2020 and be approved for listing in 2021.
Abassip injection is a CTLA4-Fc fusion protein developed by BMS that can be used in conjunction with DMARDs other than TNF-alpha inhibitors, such as methotrexate, for the treatment of patients with moderate to severe active rheumatoid arthritis who have poor dALDs.
the drug was first approved for sale in the United States in 2005 and was certified as an imported drug in China in January 2020, becoming China's first and only approved sale of CTLA4-Fc fusion protein, and the first and current lying t-cell selective co-stimulating immunomodulator in the field of autoimmune diseases.
.